Company Overview
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan ® (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Investigational product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease, sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU.
Company Information
| Established: | 1997 |
| Headquarters: | Novato, California USA |
| Stock Symbol: | NASDAQ: BMRN |
| Stock Quote: |  More  |
2009 Financial Highlights
| Total Revenue: | $315.7 Million |
| Employees: | >700 worldwide |
| Clinical Research: | Conducted internationally |
| Products: | KUVAN® for PKU, Naglazyme® for MPS VI, Aldurazyme® for MPS I |
| Commercial Operations: | Multinational |
| Clinical Pipeline: | GALNS for MPS IVA, PEG-PAL for PKU, and Utrophin upregulator for Duchenne Muscular Dystrophy |
| Focus: | Rare (Orphan) genetic diseases |
| Strategy: | Providing rapid access to treatment for patients with serious unmet medical needs, optimizing powerful biology with demonstrated potential and development clarity, accelerating approval process, strategic pipeline development |
Products
BioMarin has developed and commercialized three products in 12 years, a remarkable accomplishment in the pharmaceutical industry, and a testament to the company’s passion and dedication to patients with serious unmet medical needs. For complete safety and prescribing information, please visit www.kuvan.com, www.naglazyme.com and www.aldurazyme.com.